Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ABVC Abvc Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: ABVC
Price (delayed)
$1.68
Market cap
$28.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$29.59M
Highlights
The gross margin has surged by 112% year-on-year
Abvc Biopharma's EPS has surged by 91% YoY and by 69% QoQ
The quick ratio has declined by 38% since the previous quarter and by 20% year-on-year
ABVC's equity is down by 31% year-on-year
Key stats
What are the main financial stats of ABVC
Market
Valuations
Earnings
Shares outstanding
16.77M
Market cap
$28.18M
Enterprise value
$29.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.03
Price to sales (P/S)
49.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.2
Revenue
$508,384
Gross profit
$507,898
Operating income
-$1.95M
Net income
-$1.81M
EBIT
-$1.56M
EBITDA
-$1.24M
Free cash flow
-$1.88M
Per share
Balance sheet
Liquidity
EPS
-$0.13
EPS diluted
-$0.13
Free cash flow per share
-$0.13
Book value per share
$0.42
Revenue per share
$0.03
TBVPS
$0.99
Total assets
$14.88M
Total liabilities
$6.92M
Debt
$2.17M
Equity
$5.4M
Working capital
-$5.26M
Debt to equity
0.4
Current ratio
0.22
Quick ratio
0.2
Net debt/EBITDA
-1.13
Margins
Efficiency
Dividend
EBITDA margin
-244.8%
Gross margin
99.9%
Net margin
-356.4%
Operating margin
-384.3%
Return on assets
-14.1%
Return on equity
-31.1%
Return on invested capital
-19.7%
Return on capital employed
-19.1%
Return on sales
-306.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABVC stock price
How has the Abvc Biopharma stock price performed over time
Intraday
23.53%
1 week
46.09%
1 month
83.81%
1 year
57.01%
YTD
184.75%
QTD
58.49%
Financial performance
How have Abvc Biopharma's revenue and profit performed over time
Revenue
$508,384
Gross profit
$507,898
Operating income
-$1.95M
Net income
-$1.81M
Gross margin
99.9%
Net margin
-356.4%
The gross margin has surged by 112% year-on-year
The net margin has soared by 99% YoY and by 63% from the previous quarter
The operating margin has soared by 99% year-on-year and by 58% since the previous quarter
ABVC's net income has surged by 79% year-on-year and by 63% since the previous quarter
Price vs fundamentals
How does ABVC's price correlate with its fundamentals
Growth
What is Abvc Biopharma's growth rate over time
Valuation
What is Abvc Biopharma stock price valuation
P/E
N/A
P/B
4.03
P/S
49.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.2
Abvc Biopharma's EPS has surged by 91% YoY and by 69% QoQ
The P/B is 49% more than the last 4 quarters average of 2.7
ABVC's equity is down by 31% year-on-year
The P/S is 58% higher than the last 4 quarters average of 31.4
Efficiency
How efficient is Abvc Biopharma business performance
Abvc Biopharma's return on sales has surged by 99% YoY and by 63% QoQ
The company's return on equity has surged by 84% YoY and by 59% QoQ
The ROA has soared by 81% year-on-year and by 63% since the previous quarter
ABVC's ROIC has soared by 76% YoY and by 63% QoQ
Dividends
What is ABVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABVC.
Financial health
How did Abvc Biopharma financials performed over time
ABVC's total assets is 115% greater than its total liabilities
ABVC's total assets has surged by 97% since the previous quarter and by 2.9% year-on-year
The quick ratio has declined by 38% since the previous quarter and by 20% year-on-year
The debt is 60% less than the equity
The debt to equity has dropped by 80% since the previous quarter but it has increased by 29% year-on-year
ABVC's equity is down by 31% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.